Metabolomic analysis identifies alterations of amino acid metabolome signatures in the postmortem brain of Alzheimer’s disease

Yoon Hwan Kim, Hyun Soo Shim, Kyoung Heon Kim, Junghee Lee, Bong Chul Chung, Neil W. Kowall, Hoon Ryu, Jeongae Lee

Research output: Contribution to journalArticle

Abstract

Despite significant advances in neuroscience research over the past several decades, the exact cause of AD has not yet fully understood. The metabolic hypothesis as well as the amyloid and tau hypotheses have been proposed to be associated with AD pathogenesis. In order to identify metabolome signatures from the postmortem brains of sporadic AD patients and control subjects, we performed ultra performance liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometer (UPLC-LTQ–Orbitrap-MS). Not only our study identified new metabolome signatures but also verified previously known metabolome profiles in the brain. Statistical modeling of the analytical data and validation of the structural assignments discovered metabolic biomarkers associated with the AD pathogenesis. Interestingly, hypotaurin, myo-inositol and oxo-proline levels were markedly elevated in AD while glutamate and N-acetyl-aspartate were decreased in the postmortem brain tissue of AD patients. In addition, neurosteroid level such as cortisol was significantly increased in AD. Together, our data indicate that impaired amino acid metabolism is associated with AD pathogenesis and the altered amino acid signatures can be useful diagnostic biomarkers of AD. Thus, modulation of amino acid metabolism may be a possible therapeutic approach to treat AD.

Original languageEnglish
Pages (from-to)376-389
Number of pages14
JournalExperimental Neurobiology
Volume28
Issue number3
DOIs
Publication statusPublished - 2019 Jun 1

Fingerprint

Metabolomics
Metabolome
Brain Diseases
Alzheimer Disease
Amino Acids
Brain
Biomarkers
Inositol
Neurosciences
Amyloid
Proline
Liquid Chromatography
Neurotransmitter Agents
Hydrocortisone
Glutamic Acid
Ions
Research
Therapeutics

Keywords

  • Alzheimer’s disease
  • Amino acid metabolism
  • Biomarkers
  • Liquid chromatography mass spectrometry
  • Metabolomics

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Metabolomic analysis identifies alterations of amino acid metabolome signatures in the postmortem brain of Alzheimer’s disease. / Kim, Yoon Hwan; Shim, Hyun Soo; Kim, Kyoung Heon; Lee, Junghee; Chung, Bong Chul; Kowall, Neil W.; Ryu, Hoon; Lee, Jeongae.

In: Experimental Neurobiology, Vol. 28, No. 3, 01.06.2019, p. 376-389.

Research output: Contribution to journalArticle

Kim, Yoon Hwan ; Shim, Hyun Soo ; Kim, Kyoung Heon ; Lee, Junghee ; Chung, Bong Chul ; Kowall, Neil W. ; Ryu, Hoon ; Lee, Jeongae. / Metabolomic analysis identifies alterations of amino acid metabolome signatures in the postmortem brain of Alzheimer’s disease. In: Experimental Neurobiology. 2019 ; Vol. 28, No. 3. pp. 376-389.
@article{56ec0d94f1c64eeebcde842e892c6b77,
title = "Metabolomic analysis identifies alterations of amino acid metabolome signatures in the postmortem brain of Alzheimer’s disease",
abstract = "Despite significant advances in neuroscience research over the past several decades, the exact cause of AD has not yet fully understood. The metabolic hypothesis as well as the amyloid and tau hypotheses have been proposed to be associated with AD pathogenesis. In order to identify metabolome signatures from the postmortem brains of sporadic AD patients and control subjects, we performed ultra performance liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometer (UPLC-LTQ–Orbitrap-MS). Not only our study identified new metabolome signatures but also verified previously known metabolome profiles in the brain. Statistical modeling of the analytical data and validation of the structural assignments discovered metabolic biomarkers associated with the AD pathogenesis. Interestingly, hypotaurin, myo-inositol and oxo-proline levels were markedly elevated in AD while glutamate and N-acetyl-aspartate were decreased in the postmortem brain tissue of AD patients. In addition, neurosteroid level such as cortisol was significantly increased in AD. Together, our data indicate that impaired amino acid metabolism is associated with AD pathogenesis and the altered amino acid signatures can be useful diagnostic biomarkers of AD. Thus, modulation of amino acid metabolism may be a possible therapeutic approach to treat AD.",
keywords = "Alzheimer’s disease, Amino acid metabolism, Biomarkers, Liquid chromatography mass spectrometry, Metabolomics",
author = "Kim, {Yoon Hwan} and Shim, {Hyun Soo} and Kim, {Kyoung Heon} and Junghee Lee and Chung, {Bong Chul} and Kowall, {Neil W.} and Hoon Ryu and Jeongae Lee",
year = "2019",
month = "6",
day = "1",
doi = "10.5607/en.2019.28.3.376",
language = "English",
volume = "28",
pages = "376--389",
journal = "Experimental Neurobiology",
issn = "1226-2560",
publisher = "Korean Society for Brain and Neural Science",
number = "3",

}

TY - JOUR

T1 - Metabolomic analysis identifies alterations of amino acid metabolome signatures in the postmortem brain of Alzheimer’s disease

AU - Kim, Yoon Hwan

AU - Shim, Hyun Soo

AU - Kim, Kyoung Heon

AU - Lee, Junghee

AU - Chung, Bong Chul

AU - Kowall, Neil W.

AU - Ryu, Hoon

AU - Lee, Jeongae

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Despite significant advances in neuroscience research over the past several decades, the exact cause of AD has not yet fully understood. The metabolic hypothesis as well as the amyloid and tau hypotheses have been proposed to be associated with AD pathogenesis. In order to identify metabolome signatures from the postmortem brains of sporadic AD patients and control subjects, we performed ultra performance liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometer (UPLC-LTQ–Orbitrap-MS). Not only our study identified new metabolome signatures but also verified previously known metabolome profiles in the brain. Statistical modeling of the analytical data and validation of the structural assignments discovered metabolic biomarkers associated with the AD pathogenesis. Interestingly, hypotaurin, myo-inositol and oxo-proline levels were markedly elevated in AD while glutamate and N-acetyl-aspartate were decreased in the postmortem brain tissue of AD patients. In addition, neurosteroid level such as cortisol was significantly increased in AD. Together, our data indicate that impaired amino acid metabolism is associated with AD pathogenesis and the altered amino acid signatures can be useful diagnostic biomarkers of AD. Thus, modulation of amino acid metabolism may be a possible therapeutic approach to treat AD.

AB - Despite significant advances in neuroscience research over the past several decades, the exact cause of AD has not yet fully understood. The metabolic hypothesis as well as the amyloid and tau hypotheses have been proposed to be associated with AD pathogenesis. In order to identify metabolome signatures from the postmortem brains of sporadic AD patients and control subjects, we performed ultra performance liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometer (UPLC-LTQ–Orbitrap-MS). Not only our study identified new metabolome signatures but also verified previously known metabolome profiles in the brain. Statistical modeling of the analytical data and validation of the structural assignments discovered metabolic biomarkers associated with the AD pathogenesis. Interestingly, hypotaurin, myo-inositol and oxo-proline levels were markedly elevated in AD while glutamate and N-acetyl-aspartate were decreased in the postmortem brain tissue of AD patients. In addition, neurosteroid level such as cortisol was significantly increased in AD. Together, our data indicate that impaired amino acid metabolism is associated with AD pathogenesis and the altered amino acid signatures can be useful diagnostic biomarkers of AD. Thus, modulation of amino acid metabolism may be a possible therapeutic approach to treat AD.

KW - Alzheimer’s disease

KW - Amino acid metabolism

KW - Biomarkers

KW - Liquid chromatography mass spectrometry

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85069496263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069496263&partnerID=8YFLogxK

U2 - 10.5607/en.2019.28.3.376

DO - 10.5607/en.2019.28.3.376

M3 - Article

AN - SCOPUS:85069496263

VL - 28

SP - 376

EP - 389

JO - Experimental Neurobiology

JF - Experimental Neurobiology

SN - 1226-2560

IS - 3

ER -